The U.S. Supreme Court has agreed to take up a case involving Teva Pharmaceutical Industries Ltd.'s top selling drug, Copaxone, The Philadelphia Inquirer reports. The case could impact patent litigation, including because Teva asked the Supreme Court to require the Federal Circuit to be more deferential to lower court ruings.
Lawyer and Legal Journalist
